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Available online 26 January 2016Recently, the dinucleotide variant ss469415590 (TT/ΔG) in a novel gene, interferon lambda 4 (IFNL4), was
identiﬁed as a stronger predictor of hepatitis C virus (HCV) clearance in individuals of African ancestry compared
with rs12979860. We aimed to determine whether this variant contributes to treatment decisions in a Chinese
population. A total of 447 chronic hepatitis C (CHC) patients (including 328 treated with interferon alpha-2b
and ribavirin), 129 individuals who had spontaneously cleared HCV (SHC), and 169 healthy controls were
retrospectively investigated. ss469415590 genotyping was performed using a mass spectrometry method
(SEQUENOM). A higher proportion of SHC individuals carried the TT/TT genotype compared with CHC patients
(95.3% vs. 88.8%, P=0.027). In patients with HCV genotype 1b, the ss469415590 variant was independently as-
sociatedwith sustained virologic response (SVR) (odds ratio [OR]=3.247, 95% conﬁdence interval [CI]= 1.038–
10.159, P= 0.043) and on-treatment virological responses, including rapid (RVR), complete early (cEVR), early
(EVR), and end-of-treatment (ETVR), with a minimal OR of 3.73. Especially for patients with high viral load
(≥4 × 105 IU/ml), ΔG allele carriers had a lower chance of achieving SVR compared with those carrying the
TT/TT genotype (7.1% vs. 36.0%, P = 0.034, OR [95% CI] = 7.24 [1.02–318.45], negative predictive value =
92.9%). In patients with HCV genotype 2a, no signiﬁcant association between the ss154949590 variant and the vi-
rological responsewas identiﬁed (P N 0.05). Additionally, we found that ss154949590was in complete linkage dis-
equilibriumwith rs12979860. In conclusion, the IFNL4 ss154949590 TT/TT genotype favors spontaneous clearance
of HCV. This same variant is associatedwith treatment-induced clearance in patients with genotype 1b, but not 2a.
ss469415590 (or rs12979860) genotyping should be considered for patients with HCV genotype 1b and high viral
load when making a choice between standard dual therapy and an IFN-free direct-acting antiviral regimen.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Hepatitis C virus (HCV) infects 130 to 170million people worldwide
(Lavanchy, 2009) and up to 4 million individuals are newly infected
with HCV annually (Westbrook and Dusheiko, 2014). Up to 64–82% of
acutely infected individuals fail to clear the virus and thus developpartate aminotransferase; BMI,
se; CHC, chronic hepatitis C; CI,
esponse; EVR, early virological
titis C virus; HGB, hemoglobin;
odds ratio; RBC, red blood cell;
gle nucleotide polymorphism;
lesterol; TG, triglyceride; ULN,
nse; WBC, white blood cell.
gy, First Hospital, University of
qiniu@aliyun.com (J. Niu).
. This is an open access article underchronic hepatitis C (CHC), with as many as 10–20% progressing to cir-
rhosis over 20–30 years (Westbrook and Dusheiko, 2014).
CHC patients experience signiﬁcant differences in response to antivi-
ral therapy depending on the HCV genotype. Treatment with pegylated
interferon and ribavirin (IFN/RBV) results in a sustained virologic re-
sponse (SVR) in approximately 50% of CHC patients infected with HCV
genotype 1 and 75% of those infected with genotype 2 (Hadziyannis
et al., 2004; Manns et al., 2001). In addition to limited efﬁcacy, IFN/RBV
combination treatment is often poorly tolerated because of side effects
that prevent some patients from completing therapy.
A milestone in hepatitis C research was the discovery of genetic
markers—such as the rs12979860 and rs8099917 single nucleotide
polymorphisms—located on chromosome 19q13.13 near IFNL3 (also
known as IL28B, encoding IFNL3) that have been associated with re-
sponses to HCV treatment and spontaneous clearance of the virus in
several genome-wide association studies (Ge et al., 2009; Suppiah
et al., 2009; Tanaka et al., 2009). However, molecular investigationsthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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For instance, thesemarkers are not consistently associated with hepatic
IFNL3mRNA expression (Dill et al., 2011; Honda et al., 2010; Marukian
et al., 2011). Furthermore, Urban et al. found that the only coding poly-
morphism in IFNL3, rs8103142 (encoding a p.Arg70Lys alteration in
exon 2), which is in strong linkage disequilibrium with rs12979860
(r2= 0.8–1.0), does not seem to affect the function of the IFNL3 protein
(Urban et al., 2010). More recently, a new interferon family gene, IFNL4,
which harbors a dinucleotide variant (ss469415590) with two alterna-
tive alleles, TT or ΔG, was identiﬁed (Prokunina-Olsson et al., 2013).
The one-base deletion in the ΔG variant results in a frameshift, which in
turn produces the full-length protein designated as IFNL4, while the TT
variant does not produce IFNL4 (Prokunina-Olsson et al., 2013). IFNL4
impairs spontaneous clearance and IFNα-based treatment-induced
clearance of HCV (Prokunina-Olsson et al., 2013). A correlation between
IFNL4 polymorphisms and the activity of IFNL4 protein was conﬁrmed
and a causal link between reduced antiviral activity of the IFNL4 protein
and reduced hepatic interferon-stimulated gene (ISG) expression as
well as improved HCV clearance was established (Terczynska-Dyla
et al., 2014).
Direct-acting antiviral agents (DAA) with or without IFN/RBV yield
highly promising SVR rates (Jacobson et al., 2014; Pawlotsky, 2014).
However, DAAs are expensive and not affordable for many patients
(Drenth, 2013). Presently, these agents have not been approved in
many countries, including China. In addition, IFN-free treatment may
be associated with slightly higher relapse rates and/or drug resistance,
as reported recently with some regimens (Schinazi et al., 2014). Thus,
if a DAA treatment fails, there is an increased risk of resistant HCV
strains being selected that may compromise future treatment options
(Ciesek and Manns, 2011; Sarrazin et al., 2012). Consequently, there is
still an urgent need to distinguish the patients who might beneﬁt
from the standard regimen with IFN/RBV only based on pre-treatment
predictors of response.
In this context, our study aimed to (1) assess the association of
the novel IFNL4 polymorphism ss469415590 with spontaneous HCV
clearance, (2) evaluate the predictive value of this SNP for treatment
responses, (3) clarify the distribution of IFNL4 variants in non-SVR
patients, and (4) identify patients with a high probability of treatment
failure according to genetic variations in IFNL4, pre-treatment viral
loads, and standard biochemical variables in a Chinese population pre-
dominantly infected with HCV genotypes 1b or 2a.2. Materials and methods
2.1. Study population
A total of 745 Chinese Han adults were evaluated retrospectively. All
subjects attended the “Epidemiological investigation of hepatitis C virus
infection in FuYu country of Jilin Province” at the First Hospital of Jilin
University from 2009 to 2010. The prevalence of HCV in this area is
high as a consequence of illicit drug (caffeine sodium benzoate) use
involving shared syringes in the 1980s (data not published). Enrolled
individuals were classiﬁed into three groups: 447 patients with CHC,
129 who had spontaneously cleared HCV, and 169 healthy controls. All
subjects met the following inclusion criteria: Chinese, Han, treatment-
naïve, hepatitis B surface antigen (HBsAg)-negative, human immune de-
ﬁciency virus (HIV)-negative, andwith sufﬁcient stored DNA to perform
IFNL4 genotyping. The following exclusion criteria were employed: the
presence of decompensated liver disease, hepatocellular carcinoma, or
a previous history of antiviral therapy for CHC. Patients were considered
to have CHC if they were anti-HCV positive and HCV RNA positive in
serum. Those with spontaneous viral clearance were anti-HCV positive
and HCV RNA negative. Healthy controls were anti-HCV negative and
had no evidence of liver disease on physical examination, biochemistry
testing, and abdominal ultrasound.Written informed consent for genetic testing was obtained from
all participants, and the study protocol was approved by the Ethics
Committee of the First Hospital of Jilin University.
2.2. Treatment and follow-up
Of the 447 CHC patients, 328 had received IFN/RBV treatment in the
form of subcutaneous injections of recombinant interferon-α2b (5 MU,
three times/week; Beijing Kawin Technology Share-holding Co, Ltd.,
Beijing, China) and oral ribavirin (900 mg/day) for at least 12 weeks
and treatment compliance rates were greater than 80% before 12 weeks.
HCVRNAwas quantiﬁed atweeks 0, 2, 4, 12, 24, 36, and 48 during treat-
ment, and weeks 24, 48, and 96 after treatment cessation.
2.3. Outcomes
On-treatment responses were deﬁned as follows: ultra-rapid viro-
logical response (URVR), HCV RNA load b15 IU/ml after 2 weeks of
therapy; rapid virological response (RVR), b15 IU/ml after 4 weeks of
therapy; complete early virological response (cEVR), b15 IU/ml after
12 weeks of therapy; early virological response (EVR), a more than 2
log10 decrease in HCV RNA load from baseline after 12weeks of therapy,
and end-of-treatment virological response (ETVR), b15 IU/ml at the end
of treatment. SVR was deﬁned as HCV RNA load b15 IU/ml at least
24 weeks after the completion of therapy. Non-SVR outcomes included
null response, on-treatment viral breakthrough, and relapse. Null re-
sponse was deﬁned as viral load N15 IU/ml throughout the duration
of therapy. On-treatment viral breakthrough was deﬁned as HCV RNA
loadN15 IU/ml after an initial response (HCVRNA loadb15 IU/ml) during
treatment. Virologic relapse was deﬁned as HCV RNA load b15 IU/ml at
the end of treatment but N15 IU/ml during follow-up.
2.4. Laboratory tests
HCV genotyping in patients with CHC was performed by multicolor
ﬂuorescence PCR with an HCV RNA genotype kit (BioAssay Science &
Technology Co. Ltd., China). HCV genotyping in the SHC group was per-
formed by HCV serotyping assay using a fully automatic HISCL-5000
immunoanalyzer (Sysmex Co., Hyogo, Japan). A genotype of 1 or 2 can
be determined. In China, the overwhelming majority of HCV strains are
1b or 2a. Thus, this assay was suitable. HCV RNA levels were determined
by a real-time polymerase chain reaction assay (COBAS AmpliPrep HCV
Monitor/COBAS TaqMan HCV test, Roche, Grenzach, Germany) with a
lower limit of quantiﬁcation of 15 IU/ml. Serum alanine aminotransfer-
ase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transfer-
ase (GGT), total cholesterol (TC) and triglyceride (TG) levels, and
hemoglobin (HGB) levels, as well as white blood cell (WBC), red blood
cell (RBC), and platelet counts, were determined by routine laboratory
techniques.
2.5. IFNL4 ss469415590 genotyping
Genotyping of ss469415590 was performed using a mass spectrom-
etry method (SEQUENOM, BioMiao Biological Technology, Beijing,
China). The PCR primers were: forward 5′-ACGTTGGATGGCTCCAGCGA
GCGGTAGTG-3′; reverse 3′-ACGTTGGATGTGGGTCCTGTGCACGGTGA-
5′; and UEP ggcttTGCACGGTGATCGCAG.
2.6. Statistical analysis
Normally distributed variables are presented as mean ± standard
deviation. Differences were evaluated by the Student's t-test. Skewed
distributed variables are presented as median (range) and differences
were tested by the Wilcoxon rank-sum test. Categorical variables
are presented as numbers (percentage) and differences were assessed
using the PearsonChi-square test, linear-by-linear association, or Fisher's
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curve analysis was performed, followed by a Youden index calculation
(Youden, 1950), to identify the best cut-off value of viral load used to
distinguish SVR from non-SVR patients infected with HCV genotype 2a.
A univariate logistic regression model was used to calculate the odds
ratio (OR) with a 95% conﬁdence interval (CI) and corresponding P
value for each factor. Multivariate logistic regression models (Forward
Likelihood Ratio approach) were used to identify factors independently
associated with SVR.
All statistical testswere two-sided. A P value b0.05was considered to
be statistically signiﬁcant. Statistical analyseswere performedusing SPSS
version 18.0 software (IBM/SPSS Inc., Chicago, IL) or GraphPad Prism
version 5.00 (for Windows, GraphPad Software, San Diego California,
USA, www.graphpad.com). The accordance with the Hardy–Weinberg
equilibrium and the linkage between the two SNPs were evaluated
using the Haploview 4.2 software (Cambridge, MA, USA).3. Results
3.1. Characteristics of the 745 study subjects
The characteristics of the three groups are provided in Table 1. In the
healthy control group, the genotype frequency of ss469415590 TT/TT,
ΔG/TT, andΔG/ΔGwas 89.9%, 8.9%, and 1.2%, respectively. The frequen-
cy did not deviate signiﬁcantly from Hardy–Weinberg equilibrium
(P = 0.166). Given that few individuals carried the ΔG/ΔG genotype,
thosewithΔG/TT andΔG/ΔGwere combined in the sequential analysis.
No signiﬁcant difference in genotype frequency was observed between
healthy control group and the combination of the other two groups
(data not shown).Table 1
Characteristics of the 745 study subjects.
Characteristics HC SHC CHC
n 169 129 447
Gender, male (%) 83 (49.1) 74 (57.4) 273 (61.1)
Age (years) 41.9 ± 11.2 50.1 ± 9.3 50.9 ± 8.1
BMI (kg/m2)b 23.4 ± 3.4 23.1 ± 3.3 23.3 ± 2.9
HCV RNA level (log10 IU/ml) – 0 6.12 (5.03–
HCV RNA level ≥ 4 × 105 IU/ml – 0 283 (63.7)
HCV genotypec
1 – 20 (35.1) 208 (55.9)1
2 – 7 (12.3) 139 (37.4)2
1b + 2a – – 8 (2.2)
2a + 2c – – 1 (0.3)
undetermined – 30 (52.6) 16 (4.3)
IFNL4 ss469415590
TT/TT 152 (89.9) 123 (95.3) 397 (88.8)
ΔG/TT 15 (8.9) 6 (4.7) 48 (10.7)
ΔG/ΔG 2 (1.2) 0 (0) 2 (0.4)
TT 319 (94.4) 252 (97.7) 842 (94.2)
ΔG 19 (5.6) 6 (2.3) 52 (5.8)
ALT (IU/l) 23 (18–30) 23 (18–35) 51 (31–89)
AST (IU/l) 22 (19–27) 25 (19–31) 41 (30–67)
GGT (IU/l) 21 (15–35) 26 (17–48) 44 (24–86)
TC (mmol/l) 5.3 ± 1.2 4.9 ± 1.2 4.7 ± 1.1
TG (mmol/l) 1.0 (0.7–1.5) 1.3 (0.9–2) 1.1 (0.8–1.4
WBC (× 109/l) 6.0 (5.2–7.0) 6.0 (5.0–7.5) 5.5 (4.6–6.7
RBC (× 1012/l) 4.7 (4.5–5.2) 4.8 (4.5–5.2) 4.9 (4.4–5.2
HGB (g/l) 143 (133–155) 145 (134–156) 152 (136–1
Platelet (× 109/l) 227 (184–264) 208 (170–252) 163 (128–2
Data are presented as mean ± standard deviation, median (inter-quartile range), or as n%.
a P values were calculated between SHC and CHC.
b BMI was not available for 89, 23, and 29 individuals in the HC, SHC, and CHC groups, respe
c HCV viral genotype was not detected for 72 and 75 individuals in SHC and CHC groups res
d HCV genotype 1 versus genotype 2.
e TT/TT versusΔG/TT+ΔG/ΔG. HC, healthy control; SHC, spontaneous hepatitis C clearance;
GGT, gamma-glutamyl transferase; TC, serum total cholesterol; TG, triglyceride; WBC, white bAmong the CHC patients, the majority was infected with HCV ge-
notype 1b (56%), followed by HCV genotype 2a (37%). Only 57 SHC
patients had enough stored serum samples. Out of them, 20 (35%)
were determined as genotype 1, 7 (12%) genotype 2, and 30 (53%)
failed.
3.2. IFNL4 ss469415590 TT/TT genotype is associated with spontaneous
clearance
Patients who spontaneously cleared the virus had a higher propor-
tion of the TT/TT genotype compared with CHC patients (95.3% vs.
88.8%, P = 0.027, Pearson's Chi-square test). To test the effect of
ss469415590 genotype on the clearance by HCV genotype, the same
analysis was performed separately for those with HCV genotype 1 and
genotype 2. No signiﬁcant results were observed (both P values N0.05,
data not shown). The proportion of patients with HCV genotype 1 in
SHC group was slightly higher than that in CHC group (only patients
with genotype 1 or 2 were analyzed, P= 0.147).
In addition, CHC patients had higher ALT, AST, GGT, and HGB levels,
and lower TC,WBC, andplatelet counts comparedwith thosewho spon-
taneously cleared the virus (Table 1).
3.3. Association of IFNL4 ss469415590 polymorphism with viral load and
biochemical parameters
HCV genotype 1b-infected homozygous TT/TT carriers had a signiﬁ-
cantly higher viral load compared with ΔG allele carriers (median 6.39
and 5.95 log10 IU/ml, P = 0.021, Fig. 1A). However, these differences
were not observed in HCV genotype 2a-infected patients (Fig. 1B) or
when all CHC patients were combined (data not shown).Pa Patients treated with IFN/RBV
All Genotype 1b Genotype 2a
328 186 123
0.448 237 (72.3) 141 (75.8) 79 (64.2)
0.430 49.6 ± 7.8 50.1 ± 7.9 48.8 ± 7.2
0.514 23.4 ± 2.9 23.3 ± 2.9 23.6 ± 2.8
6.67) 6.13 (5.05–6.72) 6.33 (5.23–6.83) 5.96 (5.01–6.57)
210 (64.0) 131 (70.4) 74 (60.2)
b 0.147d 186 (56.7)1b
a 123 (37.5)2a
5 (1.5)
1 (0.3)
13 (4.0)
0.027e 292 (89) 162 (87.1) 113 (91.9)
35 (10.7) 23 (12.36) 10 (8.1)
1 (0.3) 1 (0.54) 0 (0)
0.023 619 (94.4) 347 (93.3) 236 (95.9)
37 (5.6) 25 (6.7) 10 (4.1)
b0.001 55 (32–100) 58 (38–103) 51 (27–101)
b0.001 44 (31–70) 47 (35–72) 39 (28–70)
b0.001 48 (26–91) 53 (27.5–92) 45 (23–91)
0.008 4.6 ± 1.0 4.6 ± 1.1 4.6 ± 1.0
) 0.001 1.1 (0.9–1.5) 1.1 (0.9–1.5) 1.1 (0.8–1.5)
) 0.004 5.6 (4.6–6.7) 5.7 (4.8–7) 5.5 (4.4–6.5)
) 0.864 5 (4.5–5.3) 4.9 (4.5–5.2) 5 (4.6–5.3)
64) 0.009 155 (142–166) 154.5 (143–164) 157 (141–166)
05) b0.001 163 (127–204) 162 (128–214) 163 (127–196)
ctively.
pectively, and undetermined denotes that genotyping failed by corresponding methods.
CHC, chronic hepatitis C; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
lood cell; RBC, red blood cell; and HGB, hemoglobin.
Fig. 1. Association of IFNL4 variants with baseline viral load and GGT values. Comparison between TT/TT and ΔG/TT or ΔG/ΔG in terms of viral load in HCV genotype 1b-infected patients
(A), in genotype 2a-infected patients (B), and GGT levels in HCV genotype 1b-infected patients (C). Horizontal bars represent the median.
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genotype 1b-infected homozygous TT/TT carriers comparedwithΔG al-
lele carriers (median 47 and 85 IU/l, P=0.003, Fig. 1C), all biochemical
parameters were similar in the two cohorts. There were no signiﬁcant
biochemical differences in HCV genotype 2a-infected patients or
all CHC patients who were carriers of the TT allele compared to non-
TT/TT genotypes (data not shown).
3.4. IFNL4 ss469415590 polymorphism is associated with responses to
antiviral therapy
A total of 328 Chinese patients from an IFN/RBV treatment cohort
were used to determine the association of IFNL4 SNPs with treatment
outcomes. Among all of the treated patients, the mean age was
49.6 ± 7.8 years, 237 (72.3%) were male, 186 (56.7%) were infectedFig. 2. Impact of IFNL4 ss469415590 variants on virological response rates for all patients (A), th
genotype 1b (C), and those infectedwithHCVgenotype 2a (D). Of note, nine patients infectedw
patients used to evaluate SVR was 177. P values were calculated using Pearson's Chi-square tewith genotype 1b and 123 (37.5%) were infected with genotype 2a
(Table 1).
For the overall treatment cohort, response rates during treatment
(RVR, cEVR, and EVR) and at the end of treatment (ETVR) were signiﬁ-
cantly higher in TT/TT compared with ΔG allele carriers (Fig. 2A). The
SVR difference tended toward but did not reach statistical signiﬁcance
(59.6% for TT/TT vs. 44.1% for ΔG allele carriers, P = 0.083, Pearson's
Chi-square test) (Fig. 2A).
For the HCV genotype 1b cohort, a similar trend to the overall treat-
ment populationwas observed in that TT/TT allele carriers achieved sig-
niﬁcantly higher RVR, cEVR, EVR, and ETVR rates compared with ΔG
allele carriers. Multivariate logistic regression analysis revealed that
IFNL4 ss469415590 was an independent predictor of RVR (adjusted
OR [95% CI] = 7.39 [1.84–29.7], P = 0.005), cEVR (adjusted OR [95%
CI] = 3.73 [1.4–9.922], P = 0.008), EVR (adjusted OR [95% CI] = 12.1ose infected with HCV genotype 1b (B), stratiﬁed by viral load in those infected with HCV
ith HCV genotype 1bwere lost to follow-up after the end of treatment. Thus, the number of
st or Fisher's exact test, as appropriate. ⁎ P b 0.05, ⁎⁎ P b 0.01 and ⁎⁎⁎ P b 0.001.
Table 2
Multivariate analysis of variables associated with virological responses during treatment.
Outcome Factors Adjusted OR
(95% CI)
Pmultivariate
RVR IFNL4 TT/TT vs. non-TT/TT 7.39 (1.84–29.7) 0.005
viral load b4 × 105 vs.
≥4 × 105 IU/ml
10.6 (4.83–23.2) b0.001
GGT (IU/l) 1.004 (1.001–1.008) 0.014
cEVR IFNL4 TT/TT vs. non-TT/TT 3.73 (1.4–9.922) 0.008
viral load b4 × 105 vs.
≥4 × 105 IU/ml
4.425 (1.96–9.99) b0.001
HGB (g/l) 1.017 (1.002–1.032) 0.022
EVR IFNL4 TT/TT vs. non-TT/TT 12.1 (3.94–37.1) b0.001
ETVR IFNL4 TT/TT vs. non-TT/TT 4.69 (1.48–14.8) 0.009
viral load b4 × 105 vs.
≥4 × 105 IU/ml
12.83 (3.24–50.8) b0.001
Age (years) 0.912 (0.86–0.967) 0.002
136 R. Wu et al. / Infection, Genetics and Evolution 39 (2016) 132–140[3.94–37.1], P b 0.001), and ETVR (adjusted OR [95% CI] = 4.69 [1.48–
14.8], P = 0.009) (Table 2). The SVR tended to be higher in TT/TT
carriers (47.7% for TT/TT vs. 27.3% for ΔG allele carriers), although the
difference did not reach statistical signiﬁcance (P = 0.071, Pearson's
Chi-square test) (Fig. 2B). Other potential baseline predictor variables
included younger age and lower HCV RNA load (P values b0.05), and
AST, ALT, and BMI (P values b0.1, Table 3). Multivariate logistic regres-
sion analysis showed that ss469415590 was an independent predictor
of SVR, with an adjusted OR of 3.247 (TT/TT vs. ΔG allele carriers, 95%
CI = 1.038–10.159, P = 0.043) (Table 3). Other predictive factors in-
cluded younger age (adjusted OR [95% CI] = 0.932 [0.889–0.977],
P = 0.003), lower viral load (adjusted OR [95% CI] = 9.039 [3.96–
20.65], P b 0.001), and higher AST levels (adjusted OR [95% CI] =
1.009 [1.002–1.017], P= 0.013) (Table 3). Because ALT levels strongly
correlated with AST levels (Spearman's rank correlation coefﬁcient =
0.885, P b 0.001), it was not retained as an independent predictor in
the multivariate regression model.Table 3
Baseline variables associated with SVR in patients infected with HCV genotype 1b or 2a.
Variables Genotype 1b (n = 177)
P univariate OR (95% CI) Pmultiva
Male vs. female 0.366
1.389 (0.681–2.831) –
Age (years) 0.009 0.003
0.948 (0.910–0.986) 0.932 (0.8
BMI (kg/m2) 0.09
1.095 (0.986–1.216) –
viral load b4 × 105 vs. ≥4 × 105 IU/ml b0.001 b0.001
6.146 (2.96–12.76) 9.039 (3.9
viral load b1 × 106 vs. ≥ 1 × 106 IU/ml b0.001
3.911 (2.065–7.41) –
IFNL4 TT/TT vs. non–TT/TT 0.078 0.043
2.436 (0.905–6.555) 3.247 (1.0
ALT (IU/l) 0.077
1.004 (0.9996–1.008) –
AST (IU/l) 0.061 0.013
1.006 (0.9997–1.013) 1.009 (1.0
GGT (IU/l) 0.755
0.9996 (0.997–1.002) –
TC (mmol/l) 0.58
0.921 (0.690–1.231) –
TG (mmol/l) 0.246
0.770 (0.496–1.197) –
WBC (× 109/l) 0.96
0.996 (0.860–1.154) –
RBC (× 1012/l) 0.604
0.906 (0.624–1.316) –
HGB (g/l) 0.633
1.003 (0.991–1.015) –
Platelet (× 109/l) 0.301 –
0.998 (0.994–1.002) –
Signiﬁcant differences are shown in bold.By stratifying pre-treatment viral load, we found that the
ss469415590 genotype (TT/TT vs. ΔG allele) had a more profound
impact on SVR for patients with viral loads ≥4 × 105 IU/ml (TT/TT
allele: (40/111), 36% vs. ΔG allele: (1/14), 7.1%, OR [95% CI] = 7.24
[1.02–318.45], P = 0.034, Fisher's exact test, Fig. 2C). The positive pre-
dictive value and negative predictive value were 36.0% and 92.9%,
respectively.
For the HCV genotype 2a cohort (n = 123), neither response rates
during treatment nor SVR exhibited signiﬁcant difference between
TT/TT and ΔG allele carriers, being high in both TT/TT (80%, 8/10) and
ΔG allele carriers (75.5%, 82/109, P= 0.737, Pearson's Chi-square test)
(Fig. 2D). By univariate logistic regression analysis, SVRwas signiﬁcant-
ly associatedwith high ALT, AST, GGT, andHGB levels, and low TC,WBC,
and platelet counts (P values b0.05, Table 3). The association with viral
load (b4 × 105 vs. ≥4 × 105 IU/ml) did not reach statistical signiﬁcance
(P N 0.05). UsingROC curve analysis and a subsequent Youden index cal-
culation, 1 × 106 IU/ml was identiﬁed as the best cut-off value for the
viral load to distinguish SVR from non-SVR patients infected with HCV
genotype 2a (OR [95%CI] = 3.592 [1.438–8.973], P= 0.006). However,
only high AST levels (adjusted OR [95% CI] = 1.057 [1.022–1.092])
and low WBC counts (adjusted OR [95% CI] = 0.737 [0.562–0.966])
remained as independent predictors of SVR after multivariate logistic
regression analysis (Table 3).
Data regarding the effect of biochemical factors on the virological re-
sponsewere inconsistent. By dividing the continuous values into several
groups, we found that as AST or ALT levels increased, SVR rates in-
creased signiﬁcantly, particularly in those with HCV genotype 2a infec-
tions (Fig. 3A, B). Here, all patients with a baseline AST N 70 IU/l
or ALT N200 IU/l achieved SVR, which had an increment of 37.0%
and 40.0% compared with SVR rates in those with AST ≤ 35 IU/l or
ALT ≤40 IU/l, respectively. In contrast, the increments in SVR rates
(from AST ≤ 35 to N70 and ALT ≤ 40 to N200 IU/l) were only 21.4%
(AST) and 24.7% (ALT) in HCV genotype 1b-infected patients. GGT
values only had a signiﬁcant impact on SVR in HCV genotype 2a-Genotype 2a (n = 117)
riate OR (95% CI) P univariate OR (95% CI) Pmultivariate OR (95% CI)
0.431
1.412 (0.598–3.333) –
0.131
89–0.977) 0.956 (0.901–1.014) –
0.245
1.099 (0.937–1.289) –
0.07
6–20.65) 2.403 (0.932–6.197) –
0.006
3.592 (1.438–8.973) –
0.737
38–10.16) 0.759 (0.152–3.796) –
0.002
1.024 (1.008–1.039) –
0.002 0.001
02–1.017) 1.052 (1.019–1.085) 1.057 (1.022–1.092)
0.028
1.013 (1.001–1.025) –
0.026
0.602 (0.385–0.942) –
0.128
0.627 (0.344–1.143) –
0.016 0.027
0.741 (0.581–0.945) 0.737 (0.562–0.966)
0.056
1.79 (0.986–3.249) –
0.011
1.022 (1.005–1.04) –
0.02
0.992 (0.985–0.999) –
Fig. 3. Association of biochemical variables with SVR in HCV genotypes 1b vs. 2a infections. Differences in SVR rates for serum AST (A), ALT (B), GGT (C), and TC (D) values were assessed
separately for HCV genotype 1b and 2a using a linear-by-linear association. The upper limits of normal for AST, ALT, and GGT values were 35, 40, and 50 IU/L, respectively. The range of
normal for TC was 3.1–6.1 mmol/l. ⁎ P b 0.05 and ⁎⁎⁎ P b 0.001.
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lower SVR was observed as TC levels increased in HCV genotype 2a pa-
tients, whereas no signiﬁcant changeswere observed in thosewith HCV
genotype 1b. Overall, the biochemical variables described had a more
profound impact in HCV genotype 2a-infected patients compared with
1b-infected patients.
3.5. Association of IFNL4 ss469415590 polymorphismwith treatment failure
Finally, we assessed the distribution of IFNL4 genotypes among non-
SVR patients stratiﬁed according to HCV genotypes. Non-SVR patients
were classed into three subgroups: null-responders, those with break-
through, and relapsers. Non-SVR patients infected with HCV genotype
1b included 21 null-responders, 31with breakthrough, and45 relapsers.
As shown in Fig. 4, the unfavorable genotypes ΔG/TT and ΔG/ΔG were
more common in null-responders than patients with breakthrough
(33.3% vs. 16.1%, P= 0.188) and relapsers (33.3% vs. 8.9%, P b 0.05). Of
note, the frequency ofΔG in relapsers and thosewith viral breakthrough
was similar to those who had achieved SVR (7.5%) (Fig. 4).
Among patients infected with HCV genotype 2a, only ten carried the
unfavorable genotypes. Hence, no signiﬁcant differences were observed
among the different non-SVR subgroups (data not shown).
4. Discussion
In this study, we found that compared with the IFNL4 ss469415590
TT/TT genotype, the ΔG variant is not only associated with chronic
HCV infection of HCV but also impaired responses to IFN-based treat-
ment in HCV genotype 1b-infected patients. This ﬁnding is consistent
with other studies, and the OR of the favorable (TT/TT) versus unfavor-
able (ΔG variant) genotypes of IFNL4 ss469415590 reported here waswell within the range reported among Caucasians with HCV genotype
1 infections (Covolo et al., 2014; Stattermayer et al., 2014).
Whether the ss469415590 genotype provides additional predictive
value beyond the rs12979860 genotype remains to be determined. In
two previous studies, we reported that patients who carry CC genotype
of rs12979860 have a greater likelihood of spontaneously clearing HCV
than patients who carry the T allele (Kong et al., 2014; Shi et al., 2012).
We also reported that the rs12979860 genotype is associatedwith com-
plete early, but not rapid, virological response in a cohort of 235 patients
(Shi et al., 2012). No association with rapid virological response was
found due to inadequate power. More recently, Prokunina-Olsson sug-
gested that ss469415590 is a better marker for predicting HCV clear-
ances and responses to therapy than rs12979860 in African-American
individuals, but provides comparable information in Europeans and
Asians due to high linkage disequilibrium (Prokunina-Olsson et al.,
2013). Hence, we performed a linkage disequilibrium analysis between
ss469415590 and rs12979860 in 745 ChineseHan individuals forwhom
the rs12979860 genotypinghad beenpreviously performed. In linewith
the results reported by Prokunina-Olsson et al. (Prokunina-Olsson
et al., 2013), rs12979860 was in complete linkage disequilibrium with
ss469415590 (r2 = 1) in our study. Thus, testing for ss469415590 and
rs12979860 provided an identical effect on predicting treatment re-
sponses in Chinese Han patients.
Despite its predictive value in HCV genotype 1b-infected patients,
therewere no statistically signiﬁcant associations between the IFNL4 ge-
notype and treatment responses in HCV genotype 2a-infected patients
in this study. Whether SNPs near IFNL3 inﬂuence treatment responses
and treatment decisions in patients with genotype 2 infections remains
controversial, with the results of two recent meta-analyses contradic-
ting each other (Jia et al., 2012; Schreiber et al., 2012). This controversy
may result from sample sizes and/or differences in ethnic stratiﬁcation.
Moreover, a recent adequately powered study in Caucasian patients
Fig. 4. Distribution of IFNL4 ss469415590 ΔG-included genotypes in non-SVR patients
with genotype 1b infection. ⁎ P b 0.05 and ⁎⁎ P b 0.01 (Fisher's exact test).
Fig. 5. A treatment decision guide tree constructed based on d
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that IFNL3 genotypes are the strongest baseline predictor of SVR (Eslam
et al., 2014). A recent meta-analysis showed that the favorable IFNL3 ge-
notype including rs12979860 CC genotype is a statistically signiﬁcant
predictor of SVR in Caucasian HCV genotype 2- and 3-infected patients,
but not in Asian HCV genotype 2-infected patients (Rangnekar and
Fontana, 2013). Although a statistical association was demonstrated in
these studies, the clinical utility of the IFNL3 polymorphism in individual
patients in daily practice seems limited, because comparedwith unfavor-
able genotypes, SVR rates were only increased by 5–13% in patients with
favorable IFNL3 polymorphisms (Eslam et al., 2014; Rangnekar and
Fontana, 2013; Schreiber et al., 2012).
In the present study, we documented that besides IFNL4 geno-
types, HCV RNA load and serum aminotransferase levels were im-
portant baseline predictors of IFN responsiveness in HCV genotype
1b-infected patients. For genotype 2a-infected patients, although
IFNL4 genotypes were not relevant, other factors, including serum
aminotransferases, GGT, and TC concentrations, were associated
with responsiveness. In keeping with previous reports regarding
IFNL3, we also observed a close association of IFNL4 genotypes
with pre-treatment HCV RNA load (Fischer et al., 2013; Ge et al.,
2009) and GGT values (Fischer et al., 2013), although this was re-
stricted to genotype 1b-infected patients. Interestingly, but as re-
ported previously, the favorable genotypes were strongly
associated with high HCV RNA levels (Ge et al., 2009; Oda et al.,
2014). In addition, our results revealed that biochemical variables
such as AST and ALT served as stronger pre-treatment predictors
of virological response in HCV genotype 2a- than 1b-infected pa-
tients. Similarly, GGT and TC concentrations only had a signiﬁcant
impact in HCV genotype 2a-infected patients. These results imply
an interaction between HCV genotype and hepatic inﬂammation
and/or metabolism.
The frequency of the favorable TT/TT genotype in patients with
breakthrough and relapsewas similar to thosewith SVRbut signiﬁcantly
higher than in null-responders. Previous studies of IFN/RBV retreatment
for patients who experience relapse and null-responders with HCVata derived from this study. ULN, upper limit of normal.
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rates, especially in those carrying the favorable rs8099917 TT genotype,
who achieved a SVR rate of 78% (Huang et al., 2013). Thus, DAAswith or
without IFN/RBVmight not be required in relapsed Asian patientswith a
favorable IFNL3 genotype.
It should be noted that using the best model consisting of age, viral
load, baselineAST values, and IFNL4 genotype, the outcomewas correct-
ly predicted in only approximately 70% of cases (AUC 0.786, sensitivity
0.588, speciﬁcity 0.835, positive predictive value 0.740, and negative
predictive value 0.711 for SVR). Therefore, in this context, selecting pa-
tients with a high probability of SVR or null response is desired.
We constructed a treatment decision guide tree based on data
derived from the present study (Fig. 5). As initial steps, HCV geno-
types and then viral loads should be considered. For patients infect-
ed with HCV genotype 1b and viral loads ≥4 × 105 IU/ml, IFNL4
ss469415590 or rs12979860 genotyping is suggested. If the patient
carries an unfavorable genotype (ΔG allele for ss469415590 or T al-
lele for rs12979860), the risk of failing to achieve SVR is greater than
90% (92.9%). Thus, IFN-based regimens are not recommended, while
waiting a DAA-based regimen may be a better choice. Dual therapy
with DAAs without Peg-IFN and RBV can achieve high SVR rates in
difﬁcult-to-treat patients with HCV genotype 1b infection and previ-
ous null response to Peg-IFN and RBV (Chayama et al., 2012). For
other branches of the treatment decision guide tree, treatment rec-
ommendations are not suggested due to the limited data in the
study. The cost may be a major consideration. However, it should
be noted that if the NS5A DAA is preferred, the Y93H variant of
NS5A needs to be screened for, as Itakura et al. (Itakura et al.,
2015) found that patients infected with 1b in Japan carrying the
rs8099917 beneﬁcial TT genotype had a Y93H variant rate of 27.1%,
which was signiﬁcantly higher than non-TT (9.5%). If a patient
carries Y93H, an IFN-based treatment may be a better choice, since
this variant does not affect the efﬁcacy of IFN/RBV (Itakura et al.,
2015). If the HCV genotype is 2a, IFNL4 genotyping is not suggested.
Rather, consideration should be given to serum aminotransferase
levels. If the AST (or ALT) is more than two times the upper limit
of normal (ULN), IFN/RBV treatment would be expected to result
in a high SVR (100% and 92.7%, in this study, respectively). Thus,
when the cost is also considered, IFN/RBV may be a better choice
for this group of patients.
A limitation of our study is the retrospective design. Firstly, patients
in SHC group had resolved the viruswhen the study begun, and HCV ge-
notypewas only tested in small part of the patients because not enough
frozen serum samples were available. Thus, we did not observe signiﬁ-
cant association between the IFNL4 variant and spontaneous clearance
after stratiﬁcation of HCV genotypes. However, a recent studywith pro-
spective cohort showed that both favorable IL28B genotype and HCV
genotype 1 (versus other genotypes including genotype 2) are indepen-
dent predictors of spontaneous clearance (Grebely et al., 2014). Second-
ly, this study was limited by the relatively small size, which can restrict
statistical power. This makes some results seem signiﬁcant but the
P values were not signiﬁcant.
5. Conclusions
In conclusion, the IFNL4 ss469415590 variant is associated with
spontaneous HCV clearance. Additionally, this variant is associated
with improved IFN/RBV treatment responses in Chinese patients in-
fected with HCV genotype 1b, but not with 2a. We recommend that
ss469415590 (or rs12979860) be genotyped in patients with HCV ge-
notype 1b and high viral load. If patients carry the unfavorable ΔG al-
lele for ss469415590 (or T for rs12979860), IFN-free DAA regimens
may be better options. IFNL4 genotyping can aid in clinical practice
by supplementing other previously described predictive factors when
selecting the initial treatment and/or retreatment with IFN/RBV or
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